UPDATE: Jefferies Downgrades FibroGen (FGEN) to Hold

March 2, 2021 4:35 AM EST
Get Alerts FGEN Hot Sheet
Price: $18.57 -1.28%

Rating Summary:
    5 Buy, 8 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 14 | New: 42
Trade Now! 
Join SI Premium – FREE
(Updated - March 2, 2021 6:53 AM EST)

Jefferies analyst Michael Yee downgraded FibroGen (NASDAQ: FGEN) from Buy to Hold with a price target of $45.00 (from $75.00).

The analyst comments "FGEN announced an Adcom will now be held for Roxa which means no NT approval and more pushout from 3/20 PDUFA. Math suggests mid-21 Adcom and YE21 decision which pushes everything again. Reimbursement and drug launch debate still a key issue too, putting answers into 2022 and past 12mo horizon. Stock range-bound until this all plays out. Risk went up and timelines longer. EU decision is mid-21 and still in play."

For an analyst ratings summary and ratings history on FibroGen click here. For more ratings news on FibroGen click here.

Shares of FibroGen closed at $50.53 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Downgrades

Related Entities

Jefferies & Co, PDUFA